Schering Corporation

Crucell Holland B.v.

Alexander B H Bakker

Joseph H Phillips

Lewis L Lanier

Willem Egbert Marissen

Robert Arjen Kramer

Cornelius A De Kruif

The present invention provides pharmaceutical antibody formulations, in particular liquid pharmaceutical formulations comprising anti-rabies virus antibodies. The formulations can be used in the post exposure prophylaxis of rabies.

Liquid anti-rabies antibody formulations

The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells, e.g., lymphoid and myeloid, are provided, along with methods for their use.

DAP12 nucleic acids

The invention provides binding molecules that specifically bind to rabies virus and are capable of neutralizing the virus. The invention further provides nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from rabies virus. Preferably, they can be used in the post-exposure prophylaxis of rabies.

Binding molecules capable of neutralizing rabies virus and uses thereof

MDL-1 polypeptides

Binding compounds to DAP12 proteins

Antibodies and fragments thereof to MDL-1 protein

Nucleic acids encoding mammalian cell membrane protein MDL-1

Growing community of inventors

San Francisco, CA, United States of America

Alexander B H Bakker